Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BLCO

BLCO - Bausch + Lomb Corporation Stock Price, Fair Value and News

15.71USD-0.46 (-2.84%)Market Closed

Market Summary

BLCO
USD15.71-0.46
Market Closed
-2.84%

BLCO Stock Price

View Fullscreen

BLCO RSI Chart

BLCO Valuation

Market Cap

5.7B

Price/Earnings (Trailing)

-16.86

Price/Sales (Trailing)

1.32

EV/EBITDA

18.65

Price/Free Cashflow

-43.39

BLCO Price/Sales (Trailing)

BLCO Profitability

EBT Margin

-4.66%

Return on Equity

-5.06%

Return on Assets

-2.54%

Free Cashflow Yield

-2.3%

BLCO Fundamentals

BLCO Revenue

Revenue (TTM)

4.3B

Rev. Growth (Yr)

18.05%

Rev. Growth (Qtr)

-6.31%

BLCO Earnings

Earnings (TTM)

-337.0M

Earnings Growth (Yr)

-85.56%

Earnings Growth (Qtr)

-209.26%

Breaking Down BLCO Revenue

52 Week Range

15.4620.30
(Low)(High)

Last 7 days

-3.5%

Last 30 days

8.2%

Last 90 days

9.5%

Trailing 12 Months

-18.5%

How does BLCO drawdown profile look like?

BLCO Financial Health

Current Ratio

1.7

Debt/Equity

0.68

Debt/Cashflow

0.02

BLCO Investor Care

Shares Dilution (1Y)

0.35%

Diluted EPS (TTM)

-0.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.3B000
20233.8B3.9B4.0B4.1B
20223.8B3.8B3.8B3.8B
20213.5B3.6B3.7B3.8B
20200003.4B
BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
 CEO
 WEBSITEbausch.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES13000

Bausch + Lomb Corporation Frequently Asked Questions


What is the ticker symbol for Bausch + Lomb Corporation? What does BLCO stand for in stocks?

BLCO is the stock ticker symbol of Bausch + Lomb Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bausch + Lomb Corporation (BLCO)?

As of Wed Jul 24 2024, market cap of Bausch + Lomb Corporation is 5.68 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BLCO stock?

You can check BLCO's fair value in chart for subscribers.

Is Bausch + Lomb Corporation a good stock to buy?

The fair value guage provides a quick view whether BLCO is over valued or under valued. Whether Bausch + Lomb Corporation is cheap or expensive depends on the assumptions which impact Bausch + Lomb Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BLCO.

What is Bausch + Lomb Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jul 24 2024, BLCO's PE ratio (Price to Earnings) is -16.86 and Price to Sales (PS) ratio is 1.32. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BLCO PE ratio will change depending on the future growth rate expectations of investors.